MGL-3196, a selective thyroid hormone receptor-beta agonist significantly decreases hepatic fat in NASH patients at 12 weeks, the primary endpoint in a 36 week serial liver biopsy study
EASL LiverTree™. Harrison S. Apr 13, 2018; 210658 Topic: Thyroid hormone analogs
Dr. Stephen Harrison
Dr. Stephen Harrison
Access this content in seconds by registering and creating a Free EASL Global Account here.

This content is open access (EASL members and nonmembers) as part of the educational mission of EASL.

You may also access EASL content "anytime, anywhere" with the FREE EASL LiverTree App for iOS and Android.
Full presentation open to non EASL members:
Learning Objectives
Discussion Forum (0)
Rate & Comment (0)
After viewing this presentation the participant will be able to:
- Learn about effects of a THR-B agonist MGL-3196 in patients with NASH (safety/efficacy)
Code of conduct/disclaimer available in General Terms & Conditions

By continuing to browse or by clicking “Accept Terms & all Cookies”, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies